Cost cutting is Novartis' key to sustaining high R&D spending

04/3/2011 | Wall Street Journal, The

Unlike competitors, Novartis uses cost reduction to keep its funding level for research and development "at the top of the industry," said CEO Joe Jimenez. He is optimistic about the company's ability to generate strong sales growth despite competition from generics. "We have a strategy that can lead us to grow over the next five years despite patent losses and drug price cuts," he said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ